Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. News about Disc Medicine frequently centers on its investigational pipeline, which targets fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Coverage of IRON often highlights regulatory and clinical milestones for bitopertin, DISC-0974, and DISC-3405. The company has reported submitting a New Drug Application for bitopertin in erythropoietic protoporphyria under the FDA’s accelerated approval pathway and receiving a Commissioner’s National Priority Voucher, a program designed to shorten review times for certain drugs. Updates also include progress in the APOLLO confirmatory trial of bitopertin.
Disc Medicine news also features data readouts and conference presentations. For DISC-0974, the company has reported initial Phase 2 results in anemia of myelofibrosis, describing substantial reductions in hepcidin, increases in iron, and positive effects on measures of anemia, as well as participation in major hematology meetings. For DISC-3405, Disc has announced Phase 2 and Phase 1b studies in polycythemia vera and sickle cell disease and has shared trial design information at scientific conferences.
Investors following IRON news will also see announcements related to public offerings of common stock and pre-funded warrants, updates on cash position and financial results, and corporate developments such as board changes, leadership appointments, and participation in investor and healthcare conferences. This combination of clinical, regulatory, financial, and corporate updates provides context for understanding Disc Medicine’s development-stage profile and strategic priorities.
Disc Medicine (NASDAQ:IRON) announced that company management will participate in fireside chats at three investor conferences in November 2025.
Events and times:
- Guggenheim Second Annual Healthcare Innovation Conference — Monday, November 10, 2025 at 4:30 p.m. ET
- Stifel 2025 Healthcare Conference — Thursday, November 13, 2025 at 8:40 a.m. ET
- Jefferies London Healthcare Conference — Wednesday, November 19, 2025 at 2:00 p.m. GMT
Disc Medicine (NASDAQ: IRON) priced an upsized public offering totaling 2,919,191 aggregate shares/units, including 2,619,049 new shares and 59,523 pre-funded warrants, plus 297,619 shares sold by a selling stockholder.
The public offering price is $84.00 per share (pre-funded warrant at $83.9999). Aggregate gross proceeds to Disc are expected to be approximately $225 million (before fees), and proceeds to the selling stockholder about $25 million. The underwriters have a 30-day option for up to 446,428 additional shares. The offering is expected to close on October 22, 2025. Disc intends to use net proceeds to support potential commercialization of bitopertin for EPP/XLP, fund R&D and for working capital.
Disc Medicine (NASDAQ: IRON) announced on October 20, 2025 the commencement of an underwritten offering of $220.0 million of common stock and pre-funded warrants, consisting of $200.0 million of shares offered by Disc and $20.0 million offered by AI DMI LLC (Selling Stockholder).
The underwriters have a 30-day option to purchase up to an additional $33.0 million. The offering is subject to market conditions. Disc intends to use net proceeds to support potential commercialization of bitopertin for EPP and XLP, fund research and clinical development, and for working capital and general corporate purposes.
Disc Medicine (NASDAQ:IRON) reported submission of an NDA for bitopertin in erythropoietic protoporphyria (EPP) on Sept 29, 2025, and receipt of an FDA Commissioner’s National Priority Voucher (CNPV) intended to shorten review to 1–2 months, targeting potential US approval and launch in late 2025 or early 2026. The company plans to accelerate commercial readiness and continue enrollment in the APOLLO confirmatory trial to support broader approvals.
Disc also plans near-term development for DISC-0974 (anemia of myelofibrosis) and DISC-3405 (polycythemia vera), with Phase 2 data timelines and additional trials in 2025–2026. Cash position at end of Q3 was approximately $616 million.
Disc Medicine (NASDAQ:IRON) will present Phase 1b clinical data for DISC-0974 at the 2025 American Society of Nephrology Kidney Week in Houston, Nov 6-9, 2025.
The poster (Abstract 4351248, Poster SA-PO1183) is scheduled for Nov 8, 2025 at 10:00 am CST (11:00 am EST) with Pablo Pergola, M.D., Ph.D. as presenting author. The randomized, double-blind, placebo-controlled Phase 1b study evaluates single ascending and multiple doses in nondialysis-dependent CKD patients with anemia, reporting safety, tolerability, PK, and pharmacodynamic markers including hepcidin, iron, and hematologic parameters. The abstract is available on the ASN Kidney Week website.
Disc Medicine (NASDAQ:IRON) received a Commissioner’s National Priority Voucher (CNPV) from the FDA for bitopertin in erythropoietic protoporphyria (EPP) on Oct 16, 2025.
Disc submitted a New Drug Application (NDA) in September 2025 seeking accelerated approval for patients aged 12 and older. Bitopertin holds Orphan Drug and Rare Pediatric Disease designations. The CNPV program can shorten FDA review to 1–2 months and provides enhanced communications and rolling review benefits.
Disc Medicine (NASDAQ:IRON) has submitted a New Drug Application (NDA) to the FDA for bitopertin, targeting patients aged 12 and older with erythropoietic protoporphyria (EPP). The company is pursuing accelerated approval and priority review for the drug, which has received Orphan Drug and Rare Pediatric Disease Designations.
The NDA submission is backed by positive results from the Phase 2 BEACON and AURORA studies, showing significant PPIX reductions and improvements in light tolerance, phototoxic reactions, and quality of life. The safety database includes over 4,000 clinical trial participants. If granted Priority Review, the FDA's review timeline would be reduced to 6 months instead of the standard 10 months following the 60-day filing period.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in hematologic disease treatments, has announced its participation in four major investor conferences in September 2025.
The company will engage in fireside chats at the Cantor Fitzgerald Global Healthcare Conference (Sept 3, 10:55 AM ET), Wells Fargo Healthcare Conference (Sept 4, 4:30 PM ET), H.C. Wainwright Global Investment Conference (Sept 9, 12:00 PM ET), and Morgan Stanley Global Healthcare Conference (Sept 10, 1:05 PM ET). All sessions will be accessible via webcast through Disc Medicine's investor relations website.
Disc Medicine (NASDAQ:IRON) reported Q2 2025 financial results and significant pipeline progress. The company plans to submit an NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval in October 2025, following a successful pre-NDA meeting.
Key pipeline developments include expected initial data from DISC-0974's Phase 2 study in myelofibrosis anemia and Phase 1b study in NDD-CKD anemia in Q4 2025. The company also initiated a Phase 2 study of DISC-3405 in polycythemia vera.
Financially, Disc ended Q2 with $650.0 million in cash, providing runway into 2028. Q2 net loss was $55.2 million, with R&D expenses at $46.3 million and SG&A expenses at $15.1 million.
Disc Medicine (NASDAQ:IRON) has received positive feedback from its pre-NDA meeting with the FDA regarding bitopertin, its treatment for Erythropoietic Protoporphyria (EPP). The company has confirmed plans to submit its New Drug Application (NDA) in October 2025 under the FDA's accelerated approval pathway.
CEO John Quisel expressed confidence in the alignment with the FDA regarding the submission's timing and content. The company is preparing for its first potential product launch, marking a significant milestone in bringing bitopertin to the EPP community.